HIV Infection Clinical Trial
Official title:
Closing a Critical HIV Prevention Gap: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) as Part of an HIV Combination Preventive Intervention for Sex Workers in Kolkata and Mysore-Mandya, India
Female sex workers (FSWs) in India are at high risk of HIV infection, and while correct and
consistent condom use is an effective means of preventing HIV transmission, many FSWs have
difficulty insisting on their use. Alternative HIV prevention options are needed for FSWs who
are unable to correctly and consistently use condoms with their clients or regular partners.
Oral pre-exposure prophylaxis (PrEP) may be an important tool to fill this critical
prevention gap, and a demonstration project is required to assess the impact and feasibility
of the use of PrEP as an HIV prevention intervention among most at risk FSWs in India.
The proposed project will take place at two sites in India and will assess the use of a risk
assessment tool to identify FSWs who would most benefit from PrEP, collect information about
the reasons why FSWs choose to accept or decline PrEP, evaluate two different PrEP delivery
strategies (weekly clinic pick-up or home delivery by peer educators every second day),
monitor adherence to and discontinuation of PrEP, and evaluate unintended consequences of the
use of PrEP in these communities (e.g. reduction of condom use, drug side effects or adverse
events, social harms or resistance). To ensure the safety of study participants, a community
advisory board will be set up and will meet regularly to inform study staff of any concerns
that the community may have related to the study, so that the study staff can respond in a
timely manner. A data safety and monitoring board will also be established to monitor
participant safety.
This PrEP demonstration study is designed to assess the feasibility and impact of delivering
PrEP in addition to the existing package of HIV prevention interventions available to female
sex workers in India. The study aims to: 1) identify female sex workers in need of HIV
prevention and willing to take PrEP; 2) evaluate sustained uptake and adherence to oral PrEP;
3) assess safe delivery of PrEP; and 4) demonstrate effective delivery of PrEP within the
context of the National Program of Targeted Interventions. The study will be implemented in
two regions and among two typologies of female sex workers in India: brothel-based FSWs in
Kolkata and FSWs operating from different settings in Mysore and Mandya.
Outcome 1: Identification of female sex workers in need of HIV prevention and willing to take
oral PrEP For optimal delivery with limited resources, it is critical to provide HIV
prevention strategies such as PrEP to populations at greatest risk of infection. Female sex
workers are an important population for HIV prevention in India, prioritized as a "core high
risk group" for targeted interventions by the India National AIDS Control Organization (NACO)
(NACO 2013 annual report). In particular, some FSWs report inconsistent condom use and have
unmet needs for HIV prevention (Ramesh, 2010; Reza-Paul, 2008). For example, these women may
be less empowered or able to consistently demand condom use by their clients or may wish to
become pregnant. PrEP has the potential to be an additional, more acceptable and effective
HIV prevention method for female sex workers who have difficulty using condoms consistently.
This study proposes the development and use of a risk screening tool to identify female sex
workers who are most vulnerable to HIV. This tool will guide recruitment into the
demonstration study and could later assist health providers in deciding who will benefit most
from PrEP for HIV prevention. In addition, this study will assess the proportion of FSWs
identified by the risk screening tool who are willing to take PrEP. Quantitative and
qualitative evaluations will identify factors related to the decision to initiate PrEP as
well as reasons why FSWs decline PrEP.
Outcome 2: Sustained uptake and adherence to oral PrEP among female sex workers Similar to
all medications, sustained uptake and adherence to PrEP is fundamental for efficacy in
preventing HIV acquisition. In the four clinical trials of oral PrEP that demonstrated
efficacy, study participants with high adherence had the greatest protection from HIV (Baeten
2012, Choopanya 2013, Grant 2010, Thigpen 2012). Likewise, across PrEP trials, there was a
clear relationship between higher efficacy and a greater proportion of participants with
study drug detectable in their blood. Two randomized clinical trials of daily oral PrEP among
heterosexual women in Africa found no efficacy for HIV prevention; poor adherence to PrEP
most likely explains these results (Marrazzo 2013, Van Damme 2012). For example, drug level
testing in the FEM-PrEP Study found that less than 40% of a random sample of HIV negative
women in the PrEP arm of the study had detectable levels of PrEP in their blood (Van Damme
2012). Analyses of high-risk subgroups of study participants in the Partners PrEP Study found
PrEP efficacy estimates ranged from 64 to 84%, showing consistently high efficacy of PrEP in
preventing HIV across various higher risk groups, including women (Murnane 2013).
Preliminary community awareness campaigns for PrEP among female sex workers in Kolkata found
high interest in PrEP - approximately 80% reported willingness to take daily, oral PrEP. Sex
workers in Mysore-Mandya are engaged in series of consultations where information related to
PrEP as a tool for combination prevention is being discussed and questions or concerns
related to PrEP addressed. In both places, initial observations show that there are some sex
workers (e.g. those who are on long time contracts, those with overnight clients where
sometimes the number of clients are not disclosed, those who want to be pregnant, and those
who do not use condoms with their regular partners) expressed interest in being part of the
demonstration project.
This PrEP demonstration study will assess the acceptability and feasibility of two approaches
to PrEP delivery: 1) peer educator delivery every other day; or 2) weekly clinic pick-up.
Study staff will measure PrEP initiation, adherence and discontinuation. They will record
these events in participant records, and quarterly visits will be used to assess adherence
through biological tests and questionnaires. PrEP will be delivered as part of a package of
HIV prevention services, and therefore use of other prevention strategies, such as condom
use, will also be monitored. The full package of prevention services will continue to be
provided to FSWs with the support of India's national government and in accordance with
national guidelines.
Data on drug adherence and condom use will be collected through various means. An
ethnographic study will be designed to understand factors that may promote or impede
adherence to PrEP, as well as changes in risk behaviour (reduction in condom use). In
addition to this, peer educators will use a pictorial tool to document these items (e.g.,
frequency and patterns of sexual activity, condom use, and PrEP use). The study will also
include a biological measure of PrEP adherence through the assessment of drug-levels in the
blood.
Regular counselling about HIV prevention and PrEP will be provided to study participants to
promote adherence. In a sub-sample of study participants, an electronic adherence monitoring
device to measure and promote adherence, Helping Hands, will be tested (De Blaser 2010). The
Helping Hands device is complimented by a web platform that illustrates patient-specific data
to monitor dosing history and adherence patterns.
Outcome 3: Oral HIV PrEP as part of a combined prevention package delivered safely for female
sex workers Four randomized controlled trials have demonstrated that daily, oral PrEP is safe
for HIV-uninfected women in a wide range of settings; these antiretrovirals have been proven
safe for HIV-infected women for many years of use. The most common side effects of FTC/TDF
are minor and short-lived (i.e. first several weeks). This study will provide evidence for
the safe delivery of oral PrEP to female sex workers in brothel and street-based settings in
India. Quarterly clinic visits will assess physical health, side effects, adverse events and
any other social harms or concerns with PrEP use. This study will invest in continuous
engagement with communities of female sex workers according to good participatory practice
guidelines to provide correct information about PrEP, keep communities continuously engaged,
and maintain adherence to PrEP.
A community advisory board (CAB) and a Data Safety and Monitoring Board (DSMB) will be set
up. The CAB will meet monthly and on an as needed basis. It will inform study staff of any
concerns that the community may have related to the study, so that the study staff can
respond in a timely manner. The CAB members will be close to the community and will be able
to respond to community concerns by calling meetings to address issues in a timely manner.
The DSMB will be set up to ensure that the rights of the study participants are safeguarded
in a transparent fashion, and to monitor their safety by scrutinizing any adverse events. The
DSMB will also help to respond to concerns raised by the CAB. The DSMB will include an
ethicist, a human rights lawyer, representatives from University of Manitoba, WHO and UNAIDS,
representatives from the global network of sex workers, and a statistician. In addition,
ongoing qualitative research and monitoring by research staff, as well as outreach by peer
educators, will attempt to identify any community resistance, rumours or actual harms, and
respond in an appropriate manner.
Outcome 4: Effective delivery of oral HIV PrEP demonstrated in context of National Program of
Targeted Interventions This study proposes to deliver PrEP within the context of the National
Program of Targeted Interventions in order to demonstrate that PrEP is feasible in "real
world" settings. DMSC and Ashodaya currently implement targeted intervention programs for
female sex workers in Kolkata and Mysore/Mandya, respectively. These programs provide
outreach by peer educators and outreach workers, clinic services (e.g. HIV testing and
counseling, STI screening and treatment), and referrals for HIV care and treatment for
brothel- and street-based FSWs. This study will evaluate the addition of PrEP to this
existing service delivery model. It will also show willingness of participants to enroll in a
demonstration study and to use oral PrEP without reimbursements or incentives for
participation.
Study findings can inform national and local government's decision to adopt PrEP as a new HIV
prevention strategy. Development of HIV prevention packages, provider training, quality
management and service delivery guidelines in line with national systems will provide
guidance for real life implementation of PrEP, and also contribute to the larger goal of
providing standards for the delivery of HIV prevention interventions.
Risk Mitigation Identification of willing participants: The development of a tool to
correctly identify those FSWs at continued risk of HIV infection does not ensure that those
women will be willing to take PrEP. Though initial interest in PrEP is strong in Sonagachi
among FSWs in general, women at highest risk may be different. A feasibility study to
identify levels of awareness about PrEP, perceptions and misconceptions about PrEP, and
optimum ways to present PrEP accurately to identify those women at greatest need with
greatest interest in using PrEP is about to begin in Mysore.
Research ethics: All study materials will be submitted for approval by the institutional
review boards of Durbar Mahila Samanwaya Committee (DMSC) Ethical Committee, the World Health
Organization (WHO) Ethics Review Committee (ERC), the University of Manitoba (UM) Health
Research Ethics Board (HREB), and by the Indian Council on Medical Research (ICMR) through
the Health Ministry's Screening Committee (HMSC). The procedures, risks, and benefits of
study participation will be explained to all potential study participants and informed
consent will be obtained from those who are willing to participate prior to their
participation in the study. The project will follow all guidelines for human subjects
research as mandated by the Government of India, as this is the location of the proposed
project. In addition to this, a Data Safety and Monitoring Board will be established at
Ashodaya to monitor the safety of participants and the scientific integrity of the study
across all study sites.
Community advisory board (CAB): A community advisory board will be set up in each study site,
and will meet regularly to inform study staff and the DSMB of any concerns that the community
may have related to the study, so that the study staff can respond in a timely manner.
Data Safety and Monitoring Board (DSMB): A DSMB will be established to ensure that the rights
of all study participants from each site, Ashodaya and DMSC, are safeguarded, and to monitor
their safety by scrutinizing any adverse events. They will also respond to concerns raised by
the CABs from each site. The DSMB will include an ethicist, a human rights lawyer,
representatives from the University of Manitoba, WHO and UNAIDS, representatives from the
global network of sex workers, and a statistician.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
| Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
| Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
| Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
| Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
| Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
| Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
| Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
| Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
| Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
| Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
| Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
| Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
| Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
| Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
| Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
| Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
| Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
| Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
| Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |